The impact of social frailty and physical function on laughter frequency in rheumatoid arthritis patients: data from a multicenter observational study (T-FLAG).

Objective: This study aimed to evaluate the relationship between laughter frequency, disease activity, physical function, and frailty in rheumatoid arthritis (RA) patients.

Methods: A total of 679 consecutive RA patients from a multicenter observational study conducted in 2023 were included. Laughter frequency was assessed using a standardized questionnaire, and patients were divided into the following four laughter frequency groups: 'almost every day,' '1-5 days per week,' '1-3 days per month,' and 'never or almost never.

A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis.

We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial. A total of 112 participants aged 75-90 years were randomized equally into the romosozumab and denosumab groups. Among these, 49 and 52 participants, respectively, who received their initial dose were included in the analysis.

Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis.

Aim: To compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).

Methods: This retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan-Meier curves, with the log-rank test for between-group comparisons.

Association between frailty and oral function in rheumatoid arthritis patients: A multi-center, observational study.

Objectives: This study aims to investigate the association between frailty and oral function in rheumatoid arthritis (RA) patients and to identify practical markers for early frailty detection and potential intervention strategies.

Patients And Methods: A multi-center observational cohort study (T-FLAG) included a total of 661 RA patients (186 males, 475 females; mean age: 68.5±13.

Investigation of the Risk of Frailty Progression Based on 5-Year Data in Patients With Rheumatoid Arthritis: A Multicenter Observational Study (T-FLAG).

Objectives: To examine risk factors for non-frailty rheumatoid arthritis (RA) patients progressing to frailty.

Methods: A total of 304 RA patients with records for frailty assessment based on the Japanese Cardiovascular Health Study (J-CHS) criteria from 2020 to 2024 were included. Patients classified as non-frail (J-CHS scores 0-3) in 2020 were followed annually, and those who did and did not progress to frailty were categorized into the frailty progression (n = 100) and non-frailty progression (n = 204) groups, respectively.

Discontinuation vs. continuation of concomitant methotrexate in patients with rheumatoid arthritis on certolizumab pegol: results from a randomised, controlled trial.

Objective: The present non-inferiority study was designed to compare the effect of discontinuing versus continuing methotrexate (MTX) alongside certolizumab pegol (CZP) on maintaining low disease activity (LDA) in rheumatoid arthritis (RA) patients already stable on combination therapy.

Methods: This multicentre, open-label, randomised, controlled trial included RA patients with sustained LDA (Clinical Disease Activity Index [CDAI] ≤ 10) for ≥ 12 weeks with CZP + MTX. Patients were randomised 1:1 by computer to either continue MTX (CZP + MTX group) or discontinue MTX after a 12-week reduction period (CZP group) using a dynamic allocation strategy with the minimisation method.

The association between difficult-to-treat rheumatoid arthritis and probable sarcopenia.

Objectives: To identify factors associated with probable sarcopenia in patients with rheumatoid arthritis (RA).

Methods: Probable sarcopenia was diagnosed using the SARC-F questionnaire. Patients with difficult-to-treat RA (D2T-RA) were defined as those with a history of using ≥2 biological/targeted synthetic (b/ts) disease-modifying antirheumatic drugs (b/tsDMARDs) who had moderate or high disease activity.

Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis.

Aim: The objective of this study was to compare the clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis (RA).

Methods: This study included 274 patients treated with abatacept and 241 treated with baricitinib who were followed for >52 weeks. Potential treatment selection bias was addressed by using inverse probability of treatment weighting.

Verification of grip strength as an evaluation tool for locomotive syndrome in rheumatoid arthritis.

Objectives: Locomotive syndrome (LS) leads to reduced physical function and a high risk of becoming bedridden. Grip strength serves as an indicator of upper limb and overall physical function. Rheumatoid arthritis (RA) patients with reduced grip strength frequently show finger and wrist joint inflammation.

Prevalence of social frailty in patients with rheumatoid arthritis: Data from a multicentre observational study (T-FLAG study).

Objectives: The aim of this study was to investigate the prevalence of social frailty and associated factors.

Methods: A total of 655 consecutive patients who were able to complete the Kihon Checklist (KCL) and the Questionnaire on Social Frailty between June and August 2022 were enrolled. Social frailty was assessed using the Makizako Social Frailty Index.

Factors associated with discrepancies in disease activity as assessed by SDAI and RAPID3 in patients with rheumatoid arthritis: Data from a multicentre observational study (T-FLAG).

Objectives: The present study aimed to examine discrepancies between assessments based on Routine Assessment of Patient Index Data 3 (RAPID3) and Simple Disease Activity Index (SDAI) in rheumatoid arthritis (RA) patients with controlled disease activity.

Methods: Data from 464 RA patients in SDAI remission or low disease activity (REM/LDA) were analysed. Patient-reported outcome (PRO) measures, including Health Assessment Questionnaire Disability Index (HAQ-DI), 25-question Geriatric Locomotive Function Scale (GLFS-25), and Kihon checklist (KCL), were assessed.

Associations of frailty with RA-ILD and poor control of disease activity in patients with rheumatoid arthritis: A multi-center retrospective observational study.

Background: This study aimed to investigate factors associated with frailty in rheumatoid arthritis (RA) patients.

Methods: A total of 656 RA patients were evaluated using data from an observational study in 2022. Among these patients, 152 with frailty were assigned to the frailty group, and 504 without frailty were assigned to the non-frailty group.

Well-controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T-FLAG).

Objectives: To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients.

Methods: A total of 345 RA patients who were not robust in 2021 were assigned to the improved ("robust 2022," n = 51) and non-improved ("pre-frailty/frailty 2022," n = 294) groups. Factors associated with "robust 2022" were examined by logistic regression analysis.

Relationship between frailty and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients.

Introduction: Methotrexate (MTX) is an anchor drug in the treatment of rheumatoid arthritis (RA). Frailty is the intermediate condition between being healthy and disabled, and can lead to negative health outcomes. Adverse events (AEs) due to RA drugs are expected to be higher in frail patients.

Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).

Objective: Various guidelines recommend that patients with early rheumatoid arthritis (RA) try to achieve clinical remission within 6 months, and early therapeutic intervention is important to this end. This study aimed to investigate short-term treatment outcomes of patients with early-diagnosed RA in clinical practice and to examine predictive factors for achieving remission.

Methods: Of the 210 patients enrolled in the multicenter RA inception cohort, 172 patients who were followed up to 6 months after treatment initiation (baseline) were included.

Locomotive syndrome in rheumatoid arthritis patients during the COVID-19 pandemic.

This study aimed to longitudinally evaluate the development of locomotive syndrome (LS) in rheumatoid arthritis (RA) patients during the COVID-19 pandemic using the 25-question Geriatric Locomotive Function Scale (GLFS-25). Subjects were 286 RA patients (female, 70.6%; mean age, 64.

Validation of grip strength as a measure of frailty in rheumatoid arthritis.

Rheumatoid arthritis (RA) patients often exhibit finger/wrist joint symptoms and reduced grip strength. This study aimed to validate grip strength as a measure of frailty in RA patients. Subjects were 424 female RA patients (mean age ± standard deviation, 66.

Disease activity at baseline is an independent predictor of frailty at one year in pre-frail patients with rheumatoid arthritis; a multicenter retrospective observational study.

Objectives: To investigate factors predicting frailty for one year in pre-frail patients with rheumatoid arthritis (RA).

Method: A total of 298 RA patients who were pre-frail in 2020 were evaluated in this structured, retrospective observational study. Of the 298 patients, 42 who were frail and 256 who were not in 2021 were assigned to the frailty and non-frailty groups, respectively.

Factors associated with frailty in rheumatoid arthritis patients with decreased renal function.

Objectives: To investigate factors associated with frailty in rheumatoid arthritis (RA) patients with decreased renal function.

Methods: RA patients who visited outpatient clinics from June to August 2021 were included (N = 625). Patients with estimated glomerular filtration rate <60 ml/min/1.